These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
691 related articles for article (PubMed ID: 23394705)
1. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705 [TBL] [Abstract][Full Text] [Related]
2. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia]. Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027 [TBL] [Abstract][Full Text] [Related]
3. Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen. Fedele R; Messina G; Martinello T; Gallo GA; Pontari A; Moscato T; Console G; Dattola A; Princi D; Cuzzola M; Alati C; Ronco F; Molica S; Irrera G; Martino M Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):493-500. PubMed ID: 25034142 [TBL] [Abstract][Full Text] [Related]
4. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. Ling Y; Xuan L; Xu N; Huang F; Fan Z; Guo Z; Xu X; Liu H; Lin R; Yu S; Zhang H; Jin H; Wu M; Liu C; Liang X; Ou R; Zhang Y; Liu X; Qu H; Zhai X; Sun J; Zhao Y; Liu Q J Clin Oncol; 2023 Oct; 41(29):4632-4642. PubMed ID: 37335960 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia. Xiao F; Guo H; Yan X; Qi M; Zhang J Transpl Immunol; 2024 Jun; 84():102037. PubMed ID: 38499049 [TBL] [Abstract][Full Text] [Related]
6. Comparison of a fludarabine and melphalan combination-based reduced toxicity conditioning with myeloablative conditioning by radiation and/or busulfan in acute myeloid leukemia in Japanese children and adolescents. Ishida H; Adachi S; Hasegawa D; Okamoto Y; Goto H; Inagaki J; Inoue M; Koh K; Yabe H; Kawa K; Kato K; Atsuta Y; Kudo K Pediatr Blood Cancer; 2015 May; 62(5):883-9. PubMed ID: 25545836 [TBL] [Abstract][Full Text] [Related]
7. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A; Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639 [TBL] [Abstract][Full Text] [Related]
8. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330 [TBL] [Abstract][Full Text] [Related]
9. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Rambaldi A; Grassi A; Masciulli A; Boschini C; Micò MC; Busca A; Bruno B; Cavattoni I; Santarone S; Raimondi R; Montanari M; Milone G; Chiusolo P; Pastore D; Guidi S; Patriarca F; Risitano AM; Saporiti G; Pini M; Terruzzi E; Arcese W; Marotta G; Carella AM; Nagler A; Russo D; Corradini P; Alessandrino EP; Torelli GF; Scimè R; Mordini N; Oldani E; Marfisi RM; Bacigalupo A; Bosi A Lancet Oncol; 2015 Nov; 16(15):1525-1536. PubMed ID: 26429297 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086 [TBL] [Abstract][Full Text] [Related]
11. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Gao L; Gao L; Gong Y; Zhang C; Chen XH; Zhang X Leuk Res; 2013 Nov; 37(11):1482-7. PubMed ID: 24054720 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia. Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457 [TBL] [Abstract][Full Text] [Related]
13. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512 [TBL] [Abstract][Full Text] [Related]
14. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966 [TBL] [Abstract][Full Text] [Related]
15. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia. Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217 [TBL] [Abstract][Full Text] [Related]
16. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746 [TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924 [TBL] [Abstract][Full Text] [Related]
18. Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders. Gupta A; Downey M; Shanley R; Jennissen C; Miller WP; Lund TC; Orchard PJ; Smith AR Biol Blood Marrow Transplant; 2020 Mar; 26(3):486-492. PubMed ID: 31751770 [TBL] [Abstract][Full Text] [Related]
19. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Harris AC; Boelens JJ; Ahn KW; Fei M; Abraham A; Artz A; Dvorak C; Frangoul H; Freytes C; Gale RP; Hong S; Lazarus HM; Loren A; Mineishi S; Nishihori T; O'Brien T; Williams K; Pasquini MC; Levine JE Blood Adv; 2018 Jun; 2(11):1198-1206. PubMed ID: 29844205 [TBL] [Abstract][Full Text] [Related]
20. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]